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Metabolic engineering of Saccharomyces cerevisiae
for production of very long chain fatty acid-derived
chemicals
Tao Yu1,2, Yongjin J. Zhou1,2,w, Leonie Wenning1,2, Quanli Liu1,2, Anastasia Krivoruchko1,2,3, Verena Siewers1,2,
Jens Nielsen1,2,4,5 & Florian David1,2,3
Production of chemicals and biofuels through microbial fermentation is an economical and
sustainable alternative for traditional chemical synthesis. Here we present the construction of
a Saccharomyces cerevisiae platform strain for high-level production of very-long-chain fatty
acid (VLCFA)-derived chemicals. Through rewiring the native fatty acid elongation system
and implementing a heterologous Mycobacteria FAS I system, we establish an increased
biosynthesis of VLCFAs in S. cerevisiae. VLCFAs can be selectively modiﬁed towards the fatty
alcohol docosanol (C22H46O) by expressing a speciﬁc fatty acid reductase. Expression of this
enzyme is shown to impair cell growth due to consumption of VLCFA-CoAs. We therefore
implement a dynamic control strategy for separating cell growth from docosanol production.
We successfully establish high-level and selective docosanol production of 83.5mg l 1 in
yeast. This approach will provide a universal strategy towards the production of similar high
value chemicals in a more scalable, stable and sustainable manner.
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V
ery-long-chain fatty acids (VLCFAs; 22–26 carbons) are
essential biological components, which are incorporated
in triacylglycerol molecules, sphingolipids, cuticle or
waxes1. VLCFAs such as erucic acid, as well as VLCFA-derived
products such as very-long-chain fatty alcohols (VLCFAlc)
(for example, docosanol) and very-long-chain fatty waxes
(for example, Jojoba oil) represent important classes of valuable
chemicals, which are widely used as lubricants, detergents,
polymers, photographic ﬁlm-processing agents, coatings,
cosmetics and pharmaceuticals2–5.
VLCFA chemicals are mainly extracted from natural sources or
synthesized from petrochemical feedstocks. For natural sources,
such as vegetable oils, the content of VLCFA derivatives is usually
very low and only limited sources are available. When produced
from petrochemical feedstocks, VLCFAs are synthesized
chemically through oligomerization of ethylene followed by other
modiﬁcations, which causes production cost increase with chain
length6. Thus, a more scalable, stable and sustainable production
route is needed. One promising solution is microbial production
of VLCFAs and their derivatives from renewable feedstocks7.
Here we engineered the FA metabolism for production of these
VLCFA chemicals by the yeast Saccharomyces cerevisiae, a robust
and industrially established microorganism for sustainable
production of several products on the market8. As an initial
target product we focused on docosanol, a saturated VLCFAlc
with a chain length of 22 carbons, which is used as an emollient,
emulsiﬁer, thickener in cosmetics and nutritional supplements
with a market volume of 40,000 ton per year. Furthermore,
docosanol has been approved by the Food and Drug
Administration as a pharmaceutical antiviral agent for reducing
the duration of cold sores caused by the herpes simplex virus9.
Recently, multiple efforts have been initiated on engineering
microbial FA synthesis for production of free FAs, alcohols, esters
and alkanes10–15. Most of these studies have focused on products
based on naturally abundant long-chain (LCFAs, 16–18
carbon)16, medium-chain (MCFAs, 6–14 carbon) or short-chain
(SCFAs, o6 carbon)17 FA-derived compounds. The particular
chain length can be controlled at many steps during FA synthesis.
In yeast, C16/C18 acyl-CoAs are generated by a type I FA synthase
(FAS) system, a multimeric enzyme composed of Fas1 and Fas2
subunits in an a6b6 complex16. Further elongation to VLCFAs is
carried out by membrane-embedded enzymes at the endoplasmic
reticulum by a four-step process of condensation, reduction,
dehydration and reduction18. One unit of malonyl-CoA is added
after each cycle. In bacteria, FA synthesis is carried out by a
type II FAS system, consisting of several separate enzymes.
Mycobacteria harbour a special type I FAS I for the biosynthesis
of VLCFAs, which are used as building blocks for the synthesis of
mycolic acids, major constituents of their cell envelope with a
chain length up to 90 carbons. The mycobacterial FAS I is a large
multifunctional enzyme, which catalyses the de novo synthesis
of FAs and shares homology with fungal FAS19. It produces
both C16/C18 FAs for the intrinsic cellular demand, as well
as C22/C24/C26 FAs for the speciﬁc cell wall structures
(Supplementary Table 1)20.
Unlike LCFA-, MCFA- or SCFA-derived products, total
biosynthesis of VLCFA-derived products encounters signiﬁcant
technical challenges: ﬁrst, the chain length and amount of
VLCFAs is controlled by strict cellular regulation mechanisms21;
second, considering the longer chain length, VLCFAs
biosynthesis needs much more reduction equivalents and ATP,
which will cause a higher metabolic burden; third, the low
concentration of cellular VLCFAs compared with C16/C18 FAs
requires higher activity and speciﬁcity of the converting
enzyme(s) to generate target products; fourth, the draining of
VLCFAs towards the target compound biosynthesis can cause
growth defects, as VLCFAs are necessary for essential cellular
components such as sphingolipids and nuclear envelope
structures22. Thus, VLCFA-derived molecule production
requires careful tuning and balancing of heterologous metabolic
pathways and endogenous FA metabolism.
Here we successfully engineered yeast for the targeted
production of VLCFAs and derived products thereof. As a ﬁrst
approach, we selectively modiﬁed the endogenous yeast FA
elongation system to speciﬁcally control the chain length of
VLCFAs. In a parallel approach, we demonstrated that the FAS I
system from Mycobacterium vaccae can be functionally expressed
in yeast generating a bimodal product distribution of C16–18
and C22–24 VLCFAs. Combining these two strategies, we could
selectively produce VLCFAs ranging from C22 to C26 in chain
length. Then, we further extended the metabolic pathways by
expressing a C22-speciﬁc VLCFA reductase for the production of
docosanol. To relieve the competition for VLCFAs between
product formation and cell growth-associated processes,
we implemented a dynamic control strategy for dividing the
production phase and cell growth phase, which increased
the docosanol production almost four-fold. Ultimately, by
(re)constructing the whole pathway under this dynamic control,
together with further enhancing the yeast elongation system,
mycobacterial FAS I system and the precursor supply, we enabled
a docosanol production of 83.5mg l 1, an almost 80-fold
improvement compared with the initial proof-of-concept strain.
Our results show that the FA metabolism can be engineered
for the production of VLCFA-derived chemicals in yeast.
Furthermore, for the ﬁrst time the mycobacterial FAS I system
was successfully expressed in yeast for controlling the VLCFA
chain length, representing a new and feasible strategy for targeted
high-level production of VLCFAs and derived products (Fig. 1).
Results
VLCFA chain length control by FA elongation system.
Normally, yeast generates very low amounts of VLCFAs (ZC20).
They are derived from the major FA components of C16/18 LCFAs
through several catalytic steps carried out by the intrinsic
elongation system. b-Ketoacyl-CoA synthases, also known
as elongases, catalyse the ﬁrst and rate-limiting step of the
elongation process by condensing acyl-CoA with malonyl-CoA
building blocks23. These elongases determine the substrate
speciﬁcity and ﬁnal product proﬁle of the whole elongation
system18. In S. cerevisiae, the elongases Elo1, Elo2 and Elo3 are
required for VLCFA synthesis. These elongases have different
substrate and product speciﬁcities: Elo1 has speciﬁcity for the
elongation of C12–16 to C16–18 FAs, whereas Elo2 elongates C16–18
up to C22 and Elo3 elongates C18 up to C26 (refs 18,24). We thus
modulated these elongase genes for enhancing VLCFAs pools
with chain length ZC22.
We ﬁrst engineered the VLCFAs biosynthesis in the
LCFA-CoA overproducing strain JV03, in which the LCFA-
CoA-consuming pathways including b-oxidation, triacylglycerol
(TAG) and steryl ester synthesis were deleted (CEN.PK 113-5D
are1D dga1D are2D lro1D pox1D, Fig. 2a)25. This strain JV03
produced a small fraction of C26, whereas C22 and C24 VLCFAs
were not detectable (Supplementary Fig. 1a). To drive the FA pool
towards C22, we deleted the ELO3 gene to block C26 biosynthesis,
which led to production of C22:0 VLCFAs (strain TY001,
Supplementary Figs 1b and 2b). Subsequently, the ELO2 gene
was overexpressed in JV03 elo3D strain (TY002, Supplementary
Table 5), which further increased the C22 VLCFA level by almost
1.5-fold (Fig. 2b). On the other hand, when overexpressing the
ELO3 gene in the JV03 background strain TY003, the C26 VLCFA
level increased almost twofold (Supplementary Fig. 1d). These
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results clearly showed that the chain length of VLCFAs could be
selectively modulated by engineering the intrinsic yeast
elongation system. Despite using an engineered strain, the
overall production of C22 FAs was lower than 1mg g 1 dry
cell weight (DCW).
VLCFAs chain length control by Mycobacterium FAS I system.
To overcome the limitation of the intrinsic yeast elongation
system, we focused on implementing the mycobacterial FAS
system FAS I into yeast. In mycobacteria, this multimeric enzyme
produces C16/C18 FAs for the intrinsic cellular demand, as well as
C22/C24/C26 FA precursors for speciﬁc mycobacterial cell wall
structures20,26. We attempted to establish an additional source for
VLCFAs production in yeast by expressing the M. vaccae FAS I
gene (mvfas), which can speciﬁcally generate C22/C24, as well as
C16/C18 FAs. The MvFAS was selected as it provides high levels of
C22 VLCFAs as direct precursor for docosanol production.
Compared with the multi-domain yeast Fas1/2 system, the
MvFAS lacks the phosphopantetheinyl transferase domain and
thus needs a separate acyl carrier protein synthase (Acps) to
activate the ACP with phosphopantetheine. To guarantee a
functional MvFAS, a cognate acps gene from M. vaccae was
expressed in fusion with the carboxy-terminal mvfas gene via a
3*GGGGS linker. This chimeric MvFAS-AcpS successfully
restored the growth of a FA auxotrophic yeast strain PWY12
(MATa ura3D leu2D his3D trp1D can1D fas1D::HIS3
fas2D::LEU2)27 on yeast extract peptone dextrose medium
(YPD) or complete supplement mixture (CSM) synthetic media
without FA addition (Supplementary Fig. 2). This result
demonstrated that mvfas-acps was functionally expressed in
S. cerevisiae. FA proﬁle analysis showed that mvfas-acps
expression in strain TY005 enabled a threefold increase in the
C26 VLCFA production level but only small amounts of C22 or
C24 VLCFAs were produced (Supplementary Fig. 3). The high
level of C26 VLCFA may be caused by the function of endogenous
yeast elongation system through further elongation of the C22 and
C24 FAs produced by the MvFAS. To avoid the interference, we
expressed the mvfas-acps gene in an elo2D/elo3D double knockout
strain28, which is growth deﬁcient even with VLCFAs
supplementation. Thus, an ELO3 expressing plasmid pELO3
was introduced to this strain for complementing the growth
deﬁciency (strain TDY7005). To test the mycobacterial FAS
system in this background strain, the plasmid p415GPD-MvFAS-
AcpS was introduced into strain TDY7005. These transformants
were screened for growth on 5-ﬂuoroorotic acid (5-FOA) plates
to obtain the strain TY004, which had lost the plasmid carrying
the ELO3 gene (Fig. 2c). The results showed that mvfas-acps is
able to replace the ELO3 gene in the elo2D/elo3D background
strain. Total FAs analysis of the strain TDY7005 showed that this
strain also generated C26 VLCFAs due to the overexpression of
ELO3 (Supplementary Fig. 4b), which is consistent with previous
results (Supplementary Fig. 1c). However, the strain TY004,
expressing a functional version of mvfas-acps, produced high
levels of C22 and C24 FAs as expected from the native activity of
the enzyme (Fig. 2c and Supplementary Fig. 4a).
These results show that the mycobacterial FAS I system is able
to replace both the FA synthesis (FAS1/FAS2) and elongation
(ELO2/ELO3) function in yeast. By eliminating intrinsic compet-
ing elongation reactions, we were able to selectively produce
VLCFAs with chain length of C22 and C24. Expressing MvFAS led
to almost fourfold higher production of C22 VLCFAs compared
with engineering of the endogenous yeast elongation system
(Fig. 2b,c). The increased production is likely to be the result of
two factors: (1) MvFAS can generate C16 and C18 by itself and
also can elongate the C16/C18 acyl-CoAs produced by the yeast
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Figure 1 | Schematic overview describing platform technologies and toolboxes for targeted VLCFA and derived chemical production in yeast.
LCFAs are speciﬁcally elongated to a VLCFA of choice via the intrinsic elongation system or Mycobacteria FAS I (MbFAS I) and further modiﬁed to the
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FAS and (2) using the exogenous MvFAS circumvents the
intrinsic regulation mechanisms. Thus, the mycobacterial FAS I
system allows for efﬁcient production of speciﬁc VLCFAs. In the
future, other VLCFAs could be produced via selectively choosing
the particular mycobacterial FAS system that corresponds to the
VLCFA chain length desired, as summarized in Supplementary
Table 1.
Selection of FA reductase for docosanol production. After
establishing the VLCFAs biosynthesis platform, we aimed to
engineer it towards docosanol production, a high-value VLCFA-
derived chemical (Fig. 3a). For this purpose, two main challenges
have to be faced: ﬁrst, the low level of VLCFAs asks for efﬁcient
‘terminal enzyme(s)’ to convert VLCFAs towards relevant
chemicals. Second, with much higher levels of cellular C16 and
C18 fatty acyl-CoAs, the terminal enzyme(s) should have high
catalytic speciﬁcity. For docosanol production, we tested ﬁve fatty
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Figure 3 | Engineering production of docosanol (C22H46O) in yeast.
(a) Schematic biosynthetic pathway for docosanol. AtFAR, fatty acyl-CoA
reductase from A. thaliana (AT5g22500). (b) GC–MS analysis of docosanol
production in TY002 (JV03 elo3D pELO2) with or without expression of
atfar. Statistical analysis was performed using a Student’s t-test (one-tailed;
*Po0.05, **Po0.01 and ***Po0.001; two-sample unequal variance).
At least two independent measurements were performed for each
experiment and the mean±s.d. of three biological replicates of a
representative measurement is shown. (c) Final OD600 of strains TY002
and TY012, with or without expression of the fatty acyl-CoA reductase gene
atfar. Statistical analysis was performed using a Student’s t-test (one-tailed;
*Po0.05, **Po0.01 and ***Po0.001; two-sample unequal variance).
At least two independent measurements were performed for each
experiment and the mean±s.d. of three biological replicates of a
representative measurement is shown. (d) VLCFA chain-length
proﬁles of strain TY002 (JV03 elo3D pELO2). IS (internal standard).
(e) VLCFAlc proﬁles of docosanol producing strain TY012 (JV03 elo3D
pVLCFAlc07). Typical GC–MS total ion chromatograms (TIC) of total FAs
or fatty alcohols extracted from strain TY002 (retention time from 16 to
21min) and strain TY012 (retention time from 16 to 21min). FAME and fatty
alcohols were identiﬁed by retention time and comparison with the mass
spectral library. All cells were grown as described under experimental
procedures.
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Figure 2 | Engineering production of C22 VLCFAs by FA chain-length
control in yeast. (a) Schematic overview of two strategies for chain length
control towards VLCFAs. The dotted lines indicate multiple steps and solid
lines a single step. Overexpressed genes are shown in blue (endogenous) or
green (heterologous). Competitive pathways were eliminated by deleting
corresponding genes (marked with X). Elo1, Elo2 and Elo3, yeast FA
elongases 1, 2 and 3; MbFAS, FAS I system from Mycobacterium; ScFAS,
S. cerevisiae FAS. (b) GC–MS analysis of docosanoic acid (C22:0 FAME)
generated by yeast elongation system in strains TY001 (JV03 elo3D) and
TY002 (JV03 elo3D pELO2). Statistical analysis was performed using
a Student’s t-test (one-tailed; *Po0.05; **Po0.01 and ***Po0.001;
two-sample unequal variance). At least two independent measurements
were performed for each experiment and the mean±s.d. of three biological
replicates of a representative measurement is shown. (c) GC–MS analysis
of docosanoic acid generated in strain TDY7005 (MATa lys2 ura3–52 trp1D
leu2D elo2D::kanMX elo3D::TRP1/pELO3) and strain TY004 (MATa lys2
ura3–52 trp1D leu2D elo2D::kanMX elo3D::TRP1/pGPD415-MvFAS-AcpS).
Statistical analysis was performed using a Student’s t-test (one-tailed;
*Po0.05, **Po0.01 and ***Po0.001; two-sample unequal variance).
At least two independent measurements were performed for each
experiment and the mean±s.d. of three biological replicates of a
representative measurement is shown. All cells were grown as described in
experimental procedures.
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acyl-CoA reductases that are capable of speciﬁcally converting
VLCFA-CoAs towards VLCFAlcs (AmFAR from Apis mellifera29,
AtFAR from Arabidopsis thaliana30, CfFAR from Calanus
ﬁnmarchicus29, ScFAR from Simmondsia chinensis30 and
TaFAR from Triticum aestivum31, detailed description in
Supplementary Table 8). We compared their activity in the
strains with increased C22-CoA pools. TY001 (JV03 elo3D) and
TY002 (JV03 elo3D pELO2) were transformed with the respective
plasmids resulting in strains TY006–TY015 (Supplementary
Table 2). The fatty alcohol proﬁle analysis revealed that most of
the reductases tested did not show any detectable docosanol
production, probably due to low conversion efﬁciency and
speciﬁcity (Supplementary Table 8). Only atfar expression in
strain TY002 led to the production of detectable amounts of
1.1mg l 1 docosanol (Fig. 3b and Supplementary Table 2).
Interestingly, no viable transformants were obtained when
attempting to introduce atfar expressing plasmid to the
strain TY001 (JV03 elo3D) (without ELO2 overexpression)
(Supplementary Table 2). This might be attributed to the fact
that AtFAR-deprived essential C22-CoA towards docosanol
biosynthesis. ELO2 overexpression in strain TY012 (JV03 elo3D
pVLCFAlc07) restored the cell growth possibly by providing
higher levels of VLCFAs (Fig. 2b) for both docosanol biosynthesis
and cell growth. Still, the biomass yield was much lower
(ﬁnal OD600¼ 0.3) than for the control strain without
expressing atfar (ﬁnal OD600¼ 6.0) (Fig. 3c). These results
suggested that the docosanol biosynthesis deprived the cell of
VLCFAs for cell growth. The metabolic ﬂux therefore should be
carefully balanced, to enable better cell proliferation and higher
docosanol production. Furthermore, atfar expression in yeast
resulted in speciﬁc production of docosanol (Fig. 3d,e), proving
the high selectivity of this enzyme. This speciﬁcity was also shown
previously in A. thaliana where a mutant of the atfar gene
reduced the amount of C22:0–OH in the suberin isolated from
roots and sead coats by 30%, whereas other fatty alcohols were
not affected32.
Dynamic control system to increase docosanol production. We
successfully demonstrated the concept of docosanol production in
yeast (Figs 3b and 4a). However, the titres remained very low due
to the impaired cell growth caused by deprivation of essential
precursors C22-CoA. Thus, we needed to ﬁne tune the expression
of these genes to balance cell growth and product formation.
To reach this goal, we designed a dynamic control system where
cell growth and docosanol production were separated into two
different phases by using carbon source-dependent promoters
(Fig. 4b and Supplementary Fig. 8). To make the system as
stringent and robust as possible, we tested the strategies in JV03
elo3D strain. As a ﬁrst attempt to increase cell growth with atfar
expression, we expressed ELO3 under the control of HXT1
promoter, which is activated by high level of glucose and becomes
repressed as the level of glucose decreases33. For atfar expression,
we selected HXT7, ADH2, ICL1 and GAL1 promoters33, which
are repressed by high level of glucose and activated when the cells
are in the ethanol phase or exposed to galactose as inducer,
respectively (Fig. 4b). In addition, to evaluate constitutive
expression of the atfar gene, we also tested the TDH3 and
TEF1 promoters. The results of this screening are summarized
in Supplementary Table 3 and highlighted in Fig. 4c (strains
TY016-TY027). The strain TY018, having a deletion of ELO3 and
atfar expressed under GAL1 promoter control, showed the
highest docosanol production of 4.2mg l 1, which is fourfold
higher compared with the previous proof-of-concept strain
TY012 (Figs 3b and 4c). The biomass yield was almost 80% of
the control strain TY001 (without atfar expression). Further
expression of ELO3 under HXT1 promoter control completely
restored the cell growth, but docosanol biosynthesis was totally
abolished. In the strains carrying HXT1p-ELO3, tuning the atfar
expression with promoters HXT7p or ADH2p resulted in
docosanol production of 0.8 and 0.2mg l 1, respectively, which
was much lower than the TY018 strain. These results indicated
that ELO3 disruption is essential for supplying C22-CoA for
docosanol production and a strict growth phase-dependent
control of atfar is necessary for ﬁne tuning cell growth and
increasing ﬁnal docosanol titres. In conclusion, the dynamic
control of gene expression successfully solved the growth defect
caused by precursor deprivation which laid the foundation for
high-level production of docosanol.
Efﬁcient pathway reconstruction for production of docosanol.
Although FA metabolism was successfully engineered for
docosanol production, the titre needs to be further improved.
Owing to the non-functional FA storage and degradation, the
growth rate and ﬁnal cell biomass of the JV03 background strain
are lower than that of wild-type strain25. We thus re-engineered
FA elongation and reduction towards docosanol production in
the more robust background strain CEN.PK113-5D. With the
recently established CRISPR/Cas9 technology34,35 and modular
pathway engineering36 for yeast genetic engineering, we could
easily transfer our metabolic engineering strategy to different
genetic background strains. Here we mainly focused on
integrating the genes into chromosome instead of using
episomal expression to get more stable genotypes37. We
reconstructed the entire pathway for docosanol production
including modiﬁcations regarding chain-length control,
terminal FAR enzyme expression and further optimization
using the dynamic control system (Fig. 5a). First, we deleted
ELO3 gene and integrated the atfar gene under GAL1 promoter
control at the site of ELO3 simultaneously; the resulting strain
TY028 produced 0.65mg l 1 docosanol. Further overexpressing
ELO2 gene under the control of GAL10 promoter (strain TY029)
improved the docosanol production by 4-fold (2.4mg l 1)
compared with the previous strain TY028. To provide more
acyl-CoA precursors for the endoplasmic reticulum-localized
yeast elongation system, we overexpressed ELO1 gene under
GAL7 promoter (strain TY030, Supplementary Fig. 9). However,
this modiﬁcation had only a marginal effect on docosanol
production (Fig. 5b), suggesting that precursor supply for the
elongation system in terms of acyl-CoAs seemed not to be the
rate limiting step at this point. In parallel, we aimed to further
increase FA production by integrating and overexpressing
a constitutive active version of the ACC1** enzyme
(Acc1S659A,S1157A) in strain TY028, thereby leading to
an increased precursor supply of malonyl-CoA1,38. At the same
time, we implemented the deletion of the GAL1 gene to avoid
potential inducer consumption and ensure stable GAL promoter
performance39. The resulting strain TY033 could generate
1.4mg l 1 docosanol, more than a twofold increase compared
with the previous strain TY028. If further combined with the
overexpression of ELO2 and ELO1, the docosanol production was
remarkably increased to 5.7mg l 1 (strain TY034) and
51mg l 1 (strain TY035), respectively (Fig. 5b). This highlights
that upregulating the elongation system, especially ELO1, only
becomes beneﬁcial when sufﬁcient malonyl-CoA precursors for
FA production are provided. By implementing the MvFAS
system, the production level of docosanol was further increased.
TY036, which provided increased malonyl-CoA precursor supply
through ACC1** overexpression, generated docosanol up to
40mg l 1. When combining both the yeast elongation system
and the MvFAS strategy in strain TY037, the level of docosanol
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was increased to 83.5mg l 1, an almost 80-fold increase
compared with the proof-of-concept strain TY012 (JV03 elo3D
pVLCFAlc07) (Figs 3b and 5b). Even after 80-fold improvement
in production, docosanol is still the major fatty alcohol peak
(Supplementary Fig. 5), demonstrating the high potential and
selectivity of the implemented docosanol production pathway.
Discussion
VLCFAs and their derivatives are important precursors for
valuable chemicals used in the food, drug, chemical and cosmetic
industry. Here we established a yeast-based production platform
for the production of high-value chemical docosanol. This was
accomplished by overexpressing a highly active and speciﬁc FAR
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enzyme to generate VLCFAlcs and by controlling FA chain length
towards VLCFAs.
During the last years there have been several reports on
engineering FA metabolism for long-chain FA-derived chemical
and biofuel production10,11,40–42 with the main focus on
introducing heterologous pathways to transform cellular
abundant FAs (mainly C16/18). Here we succeeded to engineer
FA metabolism towards VLCFA-derived chemical production.
Unlike abundant C16/18 FAs, the VLCFAs biosynthesis is strictly
regulated, which makes it challenging to redirect the cellular
metabolism towards the production of VLCFA-derived chemicals
with speciﬁc chain length, such as docosanol. In our study, single
modiﬁcation of VLCFA biosynthesis using the mycobacterial
MvFAS resulted in an accumulation of only C26 FA, but no C22
and C24 FAs (Supplementary Fig. 3). This suggests that the
cellular elongation system is highly interconnected with the
heterologous FAS. Thus, for the production of speciﬁc VLCFA
chemicals, the intrinsic elongation system should be carefully
tuned, depending on the target product of interest. Here we found
that disruption of ELO3 and overexpression of ELO1 and ELO2
are the best combination for increased docosanol production.
However, engineering the elongation system only produced small
amounts of docosanol (1.1mg l 1, Fig. 3b). By additionally
introducing the MvFAS system, as well as enhancing the
precursor supply, we signiﬁcantly improved docosanol
production by 80-fold to 83.5mg l 1 (Fig. 5b). A heterologous
mycobacterial FAS I system was successfully constructed by
fusing the phosphopantetheinyl transferase domain with the main
FAS enzyme and was proven to be functional and efﬁcient for
VLCFA biosynthesis, and to enable high-level docosanol
production in yeast (Fig. 5b).
Another challenge for producing VLCFA-derived chemicals is
the need for a ‘terminal enzyme’ to selectively transform the
precursor VLCFA-CoA into a relevant product, as VLCFA-CoA
levels are much lower compared with C16/C18-CoAs. Thus, an
efﬁcient and speciﬁc FAR was selected, enabling the high level
and targeted production of docosanol (Fig. 3e and Supplementary
Fig. 5b). However, an efﬁcient FAR might drain VLCFA-CoA
precursors towards the end product, resulting in insufﬁcient
VLCFAs supply for cell growth. Correspondingly, we observed
that constitutive expression of atfar decreased the biomass yield
signiﬁcantly (Fig. 3c). This is counterproductive as a certain
amount of biomass is necessary to enable high-level production of
the product of interest. The problem was solved by ﬁne-tuning
target gene expression using galactose-inducible promoters,
thereby dynamically controlling the product pathway and
separating the cell growth from the docosanol production phase.
Targeted pathway overexpression and control via GAL promoters
were previously used to optimize artemisinin production. The
strategy was applied to avoid build-up of any potentially toxic
intermediates in the mevalonate pathway, which may have
resulted in strain instability39. Furthermore, in our study the
strains beneﬁted from this effect. When implementing the
constitutively active version of the Acc1 enzyme, high levels of
precursor are generated but at the same time this strain shows
high instability10, possibly due to signiﬁcant deprivation of the
acetyl-CoA pool. To further improve docosanol production in the
future, different strategies for increasing cytosolic acetyl-CoA
supply could be evaluated43.
Recently, several studies showed the reconstruction of fatty
acyl-CoA16,44 or FA10 reduction pathways in S. cerevisiae, which
enabled the production of about 100–300mg l 1 fatty alcohols
with a chain-length mixture of C10–C18. Although facing
additional challenges when producing VLCFAs and derived
products, we reached a similar range in our studies with a ﬁnal
docosanol titre of 83.5mg l 1 with high purity.
These results clearly demonstrate that we were successful in
establishing and combining three main platforms facilitating
targeted VLCFAs and derived chemicals production in yeast
(Fig. 1): (1) providing increased precursor supply for FA
production, (2) tuning of yeast elongation system and choice of
mycobacterial FAS I system for targeted chain length control of
VLCFAs, and (3) choice of terminal enzyme and dynamic
pathway control to generate the ﬁnal product of interest.
Our ﬁndings suggest that other chain length VLCFAs could be
produced in a similar manner by tuning endogenous elongases,
along with selection of the appropriate mycobacterial FAS I
system. Depending on the background strains used and the
terminal enzyme of choice, this technology would enable the
production of various VLCFAs and derived products. These can
be used for both bulk and specialty chemicals. In biobased
production, the rate and yield on glucose are the main
determinants for production costs, and hereby determining the
cost competitiveness on the market. For low-priced bulk
chemicals such as, for example, erucic acid, one has to operate
near the theoretical yield, whereas for high-priced products, for
example, waxes for cosmetics, lower yields are acceptable. At the
same time, for products with higher chemical complexity more
engineering has to be done to facilitate production. We show in
this study that we were able to establish a production platform
where we targeted several modiﬁcations, such as FA chain length
and speciﬁc conversion to a C22 fatty alcohol, and even though
we reach reasonable titres, further improvements are required to
reach a commercial process.
However, our proof-of-principle demonstration that yeast can
be used for production of long-chain fatty alcohols will facilitate
the construction of microbial cell factories for the production of
various new products in this area, in particular considering that
industry favours the use of yeast as a robust and industrially
established production host.
Methods
Strains and reagents. Primers, plasmids and S. cerevisiae strains used are listed in
Supplementary Tables 4, 5 and 7. PrimeStar DNA polymerase was purchased from
TaKaRa Bio. Taq DNA polymerase, restriction enzymes, DNA gel puriﬁcation and
plasmid extraction kits were purchased from Thermo Scientiﬁc. The Gibson
Assembly Cloning Kit was purchased from NEB. Yeast plasmid Miniprep I kits
were purchased from Zymo Research. All oligonucleotides (Supplementary
Table 4) were synthesized at Sigma-Aldrich. All chemicals including analytical
standards were purchased from Sigma-Aldrich, unless stated otherwise. All codon
optimized heterologous genes were synthesized (Genscript) and listed in
Supplementary Table 6.
Strain cultivation. Yeast strains for preparation of competent cells were cultivated
in YPD consisting of 10 g l 1 yeast extract (Merck Millipore), 20 g l 1 peptone
(Difco) and 20 g l 1 glucose (Merck Millipore). Strains containing URA3 marker-
based plasmids or cassettes were selected on synthetic complete media without
uracil, which consisted of 6.7 g l 1 yeast nitrogen base without amino acids
(Formedium), 0.77 g l 1 CSM without uracil (Formedium), 20 g l 1 glucose
(Merck Millipore) and 20 g l 1 agar (Merck Millipore). The URA3 maker was
removed and selected against on synthetic complete mediaþ 5-FOA plates, which
contained 6.7 g l 1 yeast nitrogen base, 0.77 g l 1 CSM and 0.8 g l 1 5-FOA.
Strains containing the kanMX cassette were selected on YPD plates containing
200mg l 1 G418 (Formedium). Shake ﬂask batch fermentations for the
production of fatty alcohols were carried out in minimal medium10,45 containing
30 g l 1 glucose with or without 0.5% galactose supplemented with 60mg l 1
uracil if needed. Cultures were inoculated, from 24 h precultures, at initial OD600 of
0.05 in 15ml minimal medium and cultivated at 200 r.p.m., 30 C for 72 h. For
Dfas1/Dfas2 strain, C16 (5mM palmitic acid) and C18 (5mM stearic acid) free FAs
were dissolved in ethanol/Tween 20 (1:1) to get 100ml 100 FA stock medium,
then sterilized by membrane ﬁltration were and added as described before27.
Synthetic genes. S. cerevisiae codon-optimized synthetic genes of cffar (GenBank:
AEO89345.1), atfar (NCBI reference sequence: NP_197642.1), amfar (NCBI
accession number ADJ56408), scfar (NCBI accession number AF149917), tafar
(TAA1a; NCBI accession number CAD30692), acps (NCBI reference sequence:
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WP_040539704.1) and mvfas (NCBI reference sequence: WP_003928293.1) were
synthesized by GenScript, Inc. (Supplementary Table 6).
Construction of elo3DH kanMX. Oligonucleotide primers are listed in
Supplementary Table 4. To delete ELO3, the Del1 (LoxP-ﬁrst half kanMX gene)
fragment was ampliﬁed by primer pair pTY001/pTY002 using the plasmid
pJET1.2-Del1 as template. The 502 bp upstream of the ELO3 gene was ampliﬁed
from CEN.PK113-11C genomic DNA with primer pair pTY005/pTY006. The
upstream ELO3 region was fused by fusion PCR with the Del1 fragment to obtain
the fragment Upstream ELO3-LoxP-ﬁrst half kanMX. The Del2 fragment (second
half of kanMX gene (þ overlap)-GAL-promoter-Cre.recombinase-LoxP) was
ampliﬁed by primer pair pTY003/pTY004 using the plasmid pJET1.2-Del2 as a
template. The 500 bp downstream of ELO3 gene was ampliﬁed from CEN.PK113-
11C genomic DNA with primer pair pTY007/pTY008. The downstream ELO3
region was fused with the Del2 fragment to obtain Downstream ELO3 second half
of kanMX gene (þ overlap)-GAL-promoter-Cre.recombinase-LoxP. Both fusion
constructs were then used for co-transformation of strain JV03 to obtain strain
TY001. The transformants were selected on G418 plates. Clones were veriﬁed by
colony PCR using primer pairs pTY009/pTY002 and pTY010/pTY003. The ELO2
gene was ampliﬁed from CEN.PK113-11C genomic DNA with primer pair
pTY024/pTY025. The backbone vector pSPGM2 was digested by BamHI. The
ELO2 gene was ligated into the BamHI site of pSPGM2 to generate pELO2 by
Gibson cloning. pELO2 was used to transform strain TY001 to generate TY002.
Construction of expression plasmid pSPGM2-MvFAS-AcpS. The pSPGM2-
MvFAS-AcpS was assembled on a yeast plasmid backbone pSPGM2 by using a
modular pathway engineering strategy as described before46. In detail, the vector
pSPGM2 was ampliﬁed by primer pair pTY011/pTY012. The whole expression
cassette MvFAS-(GGGGS)3-AcpS was assembled using four parts: MvFAS2,
MvFAS3, MvFAS4 and acps. These four parts have homologous overhangs among
each other. In addition, MvFAS2 shared homologous overhangs with the TEF1
promoter of pSPGM2. The acps part shared homologous overhangs with the CYC1
terminator of pSPGM2. The MvFAS2 was ampliﬁed by primer pair pTY013/
pTY014. The MvFAS3 was ampliﬁed by primer pair pTY015/pTY016. The
MvFAS4 was ampliﬁed by primer pair pTY017/pTY018. The acps was ampliﬁed by
primer pair pTY019/pTY020. The primer pTY019 has the 3*GGGGS sequence.
All ﬁve parts were transformed into TDY7005 (Dfas1/Dfas2) and transformants
were selected on YPD plates without any FA. Clones were veriﬁed by colony PCR.
Subsequently, 3–4 clones with correct module integration were cultivated overnight
in YPD liquid medium (Supplementary Fig. 6).
Functional replacement of ELO2/3 gene by MvFAS. The p415GPD-MvFAS-
AcpS plasmid was assembled with a yeast plasmid backbone p415GPD by using a
modular pathway engineering strategy as described before. In detail, the vector
p415GPD was ampliﬁed by primers pTY022/pTY080. The whole expression
cassette MvFAS-(GGGGS)3-AcpS was assembled in three parts: GPD-MvFAS2,
MvFAS3 and MvFAS4-AcpS-CYC1t. These three parts have homologous regions
between each other. The GPD (TDH3) promoter was ampliﬁed by primer pair
pTY021/pTY022. The MvFAS2 was ampliﬁed by primer pair pTY023/pTY014.
Then, the GPD promoter and MvFAS2 were fused together by overlapping PCR to
obtain fragment GPD-MvFAS2. MvFAS3 was ampliﬁed with primer pair pTY015/
pTY016. MvFAS4-AcpS-CYC1t was ampliﬁed by primer pair pTY017/pTY081
using pSPGM2-MvFAS-AcpS as template. Then, all the ﬁve parts were transformed
into TDY7005 (Delo2/Delo3/pELO3) and transformants were selected on SD-LEU
plates. These transformants were screened for growth on 5-FOA plates. Surviving
clones were veriﬁed by colony PCR. Randomly, ten colonies were identiﬁed that
had lost the plasmid that carried the URA3 marker and the ELO3 gene.
Construction of FAR expression plasmids. Codon-optimized synthetic genes of
cffar, atfar, amfar, scfar and tafar were ampliﬁed by primer pairs pTY026/pTY027,
pTY028/pTY029, pTY034/pTY035, pTY030/pTY031 and pTY032/pTY033,
respectively. These FAR fragments were each ligated into the SpeI/NotI site of
pSPGM2 to generate pVLCFAlc03, pVLCFAlc02, pVLCFAlc01, pVLCFAlc04 and
pVLCFAlc05 via Gibson cloning. These plasmids were employed to transform
TY001 (JV03 Delo3) to generate the strains TY008, TY007, TY006, TY009 and
TY010. The respective FAR fragments were also ligated into the SpeI/NotI site of
pELO2 to generate pVLCFAlc08, pVLCFAlc07, pVLCFAlc06, pVLCFAlc09 and
pVLCFAlc10 via Gibson cloning. These plasmids were used to transform TY001
(JV03 Delo3) to generate the strains TY013, TY012, TY011, TY014 and TY015
(Supplementary Fig. 7).
Construction of plasmids for expression of AtFAR. The promoters ADH2p,
ICL1p, GAL1p, TEF1p, TDH3p and HXT7p were ampliﬁed from CEN.PK113-11C
genomic DNA with primer pairs pTY036/pTY038, pTY039/pTY041, pTY042/
pTY044, pTY045/pTY060, pTY049/pTY062 and pTY047/pTY064 separately.
The atfar gene was ampliﬁed by the primer pair pTY051/pTY052. The fragment
FBA1t was ampliﬁed from CEN.PK113-11C genomic DNA with the primer pair
pTY053/pTY054. The plasmid p416GPD was digested by SacI and KpnI, and the
promoter ADH2p; the ampliﬁed atfar fragment and the FBA1 terminator were
ligated into the SacI/KpnI site of p416GPD to generate the plasmid pDynCon05 via
Gibson assembly. The same strategy was used to construct plasmids pDynCon06,
pDynCon03, pDynCon02, pDynCon01 and pDynCon04. These plasmids were
used to transform TY001 (JV03 Delo3) to generate the strains TY020, TY021,
TY018, TY017, TY016 and TY019. To construct another set of plasmids, the
promoters ADH2p, ICL1p, GAL1p, TEF1p, TDH3p and HXT7p were ampliﬁed
from CEN.PK113-11C genomic DNA with primer pairs pTY037/pTY038, pTY040/
pTY041, pTY043/pTY044, pTY046/pTY060, pTY050/pTY062 and pTY048/
pTY064. The ELO3 gene was ampliﬁed from CEN.PK113-11C genomic DNA
with primer pair pTY055/pTY056. The HXT1p promoter was ampliﬁed from
CEN.PK113-11C genomic DNA with primer pair pTY057/pTY058. In the fol-
lowing, the fragments ELO3, HXT1p, ADH2p, atfar and FBA1t were ligated into
the SacI /Hindlll site of the p416GPD vector to generate the plasmid pDynCon11.
The same strategy was used to construct the plasmids pDynCon12, pDynCon09,
pDynCon08, pDynCon07 and pDynCon10. These plasmids were used to transform
TY001 (JV03 Delo3) to generate strains TY026, TY027, TY024, TY023, TY022 and
TY025 (Supplementary Fig. 8).
Reconstruction of the docosanol pathway. To select for speciﬁc genomic RNAs
targeting for GAL1 and ELO3, all potential gRNAs were compared with all
potential off-targets in the entire CEN.PK113-7D genome using the Yeastriction
webtool34, which is freely available at http://yeastriction.tnw.tudelft.nl. For deletion
of GAL1, the 2 mm fragment of pROS13 was ampliﬁed by primer pair pTY067/
pTY068. The linearized backbone of pROS13 was ampliﬁed by pTY102. The 2 mm
fragment and the backbone of pROS13 and were fused using Gibson Assembly to
generate the gRNA expression vector pROS13-gRNA:GAL1. To repair the double-
strand break of GAL1, primers comprised of 2 60 bp sequences homologous to
up- and downstream regions of GAL1 were used. The correct colonies were
conﬁrmed by primer pair pTY042/pTY073. To repair the double-strand break of
GAL1 and integrate the ACC1** (Acc1S659A,S1157A) gene38, ACC1** was ampliﬁed
by primer pair pTY071/pTY072, which comprised 100 bp overhang sequences
homologous to up- and downstream regions of GAL1. The gRNA expression vector
and repair fragment or primers were used to transform the IMX581 strain to
generate strain TY031. Correct strains were conﬁrmed by primer pairs pTY042/
pTY075 and pTY073/pTY074. For deletion of ELO3, the 2 mm fragment of pROS10
was ampliﬁed by primer pair pTY069/pTY070. The linearized backbone of pROS10
was ampliﬁed by primer pTY102. The 2 mm fragment and the backbone of pROS13
were fused using Gibson Assembly to get the gRNA expression vector pROS10-
gRNA:ELO3. The double-strand break of ELO3 was repaired by primer pair
pTY065/pTY066, which comprised 60 bp sequences homologous to both up- and
downstream regions of ELO3. The gRNA expression vector and repair primers
were employed to transform strain TY031 to obtain TY032. Correct colonies were
conﬁrmed by primer pair pTY076/pTY077. To repair the double-strand break of
ELO3 and integrate the atfar gene under control of the GAL1 promoter, the
upstream fragment of ELO3 was ampliﬁed from CEN.PK113-11C genomic DNA
with primer pair pTY094/pTY095. The GAL1p promoter was ampliﬁed from
CEN.PK113-11C genomic DNA with primer pair pTY096/pTY097. The atfar gene
was ampliﬁed by primer pair pTY087/pTY086 and the FBA1t terminator was
ampliﬁed from CEN.PK113-11C genomic DNA with primer pair pTY088/pTY089.
In addition, the downstream region of ELO3 was ampliﬁed from CEN.PK113-11C
genomic DNA with primer pair pTY091/pTY092. Then, the ﬁve fragments were
fused together by overlapping fusion PCR to obtain integration cassette ELO3up-
GAL1p-AtFAR-FBAt-ELO3dw. The gRNA expression vector and repair fragment
were used to transform TY031 or IMX581 to generate the strains TY033 and
TY028, respectively. To repair the double-strand break of ELO3 and integrate the
atfar gene and ELO2 gene, the upstream fragment of ELO3 was ampliﬁed from
CEN.PK113-11C genomic DNA with primer pair pTY078/pTY079. In addition,
the CYC1 terminator was ampliﬁed from CEN.PK113-11C genomic DNA with
primer pair pTY080/pTY081 and the ELO2 gene was ampliﬁed from CEN.PK113-
11C genomic DNA with primer pair pTY082/pTY083. The bidirectional promoter
GAL1p/GAL10p was ampliﬁed from CEN.PK113-11C genomic DNA with primer
pair pTY084/pTY085. Atfar was ampliﬁed by primer pair pTY086/pTY087 and the
FBA1t terminator was ampliﬁed by primer pair pTY088/pTY089. The downstream
region of ELO3 was ampliﬁed from CEN.PK113-11C genomic DNA with primer
pair pTY091/pTY092. Then, these fragments were fused together by overlapping
PCR to generate the two integration cassettes ELO3up-CYC1t-ELO2-GAL10-
GAL1p and GAL10-GAL1p-AtFAR-FBA1t-ELO3dw. The gRNA expression vector
and repair fragment were used to transform TY031 or IMX581 to generate the
strains TY034 and TY029, respectively. To repair the double-strand break of ELO3
and integrate the atfar gene and ELO2, the upstream fragment of ELO3 was
ampliﬁed from CEN.PK113-11C genomic DNA with primer pair pTY073/pTY093.
The TDH2 terminator was ampliﬁed from CEN.PK113-11C genomic DNA with
primer pair pTY103/pTY104. The ELO1 gene was ampliﬁed from CEN.PK113-11C
genomic DNA with primer pair pTY105/pTY106. The GAL7 promoter was
ampliﬁed from CEN.PK113-11C genomic DNA with primer pair pTY100/pTY101.
The CYC1 terminator was ampliﬁed from CEN.PK113-11C genomic DNA with
primer pair pTY080/pTY081. The ELO2 gene was ampliﬁed from CEN.PK113-11C
genomic DNA with primer pair pTY082/pTY083. The bidirectional promoter
GAL1p/GAL1p was ampliﬁed from CEN.PK113-11C genomic DNA with primer
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pair pTY084/pTY085. The atfar was ampliﬁed by primer pair pTY086/pTY087.
The FBA1t terminator was ampliﬁed by primer pair pTY088/pTY089. The
downstream region of ELO3 was ampliﬁed from CEN.PK113-11C genomic DNA
with primer pair pTY091/pTY092. Then, these fragments were fused together by
overlapping PCR to obtain the two integration cassettes ELO3up-TDH2t-ELO1-
GAL7p-CYC1t-ELO2 and ELO2-GAL10p-GAL1p-AtFAR-FBAt-ELO3dw. The
gRNA expression vector and repair fragments were used to transform TY031 or
IMX581 to generate strains TY035 and TY030, respectively. The strains TY033 and
TY035 were transformed with plasmid pSPGM2-MvFAS-AcpS to generate the
strains TY036 and TY037 (Supplementary Figs 9 and 10).
Total FA identiﬁcation and quantiﬁcation using GC–MS. Brieﬂy, cell pellets were
collected from 20ml cell culture and then freeze dried for 48 h. Ten milligrams or
40 OD600 of cell culture was prepared in an extraction tube. As extraction solvent, a
solution of 1ml hexane and 2ml of 14% BF3 in MeOH was used, which contained
heneicosylic acid (C21:0, FA) as an internal standard. Subsequently, samples were
ﬂushed with N2 gas (B30 s) to remove air and the lid was closed tightly. The
transesteriﬁcation was performed using a microwave treatment by programming
the heating programme to increase from room temperature to 120 C (within
6min) and then keep the temperature at 120 C for 5min. Two millilitres of
Milli-Q (MQ) water were added after the samples had been cooled down to room
temperature. Samples were vortexed (20 s) and centrifuged at 2,000 g for 5min. The
upper phase (hexane phase that contained the fatty acid methyl esters (FAMEs))
was transferred into a GC glass vials. The samples were analysed by gas chroma-
tography (GC; Focus GC, Thermo Fisher Scientiﬁc, USA) equipped with a Zebron
ZB-5MS GUARDIAN capillary column (30m 0.25mm 0.25 mm, Phenomenex)
and a DSQII mass spectrometer (Thermo Fisher Scientiﬁc)47. The GC programme
was as follows: initial temperature of 50 C, hold for 5min; ramp to 140 C at a rate
of 10 Cmin 1 and hold for 10min; ramp to 310 C at a rate of 15 Cmin 1 and
hold for 7min. The GC programme for fatty alcohol quantiﬁcation was as follows:
initial temperature of 45 C hold for 2.5min; ramp to 220 C at a rate of
20 Cmin 1 and hold for 2min; ramp to 300 C at a rate of 20 Cmin 1 and hold
for 5min. The temperature of inlet, mass transfer line and ion source were kept at
250 C, 300 C and 230 C, respectively. The ﬂow rate of the carrier gas (helium)
was set at 1.0mlmin 1 and data were acquired at full scan mode (50–650m/z).
Final quantiﬁcation was performed with Xcalibur software.
Fatty alcohol identiﬁcation and quantiﬁcation. For fatty alcohol identiﬁcation
and quantiﬁcation, cell pellets were collected from 5ml cell cultures and then freeze
dried for 72 h. As extraction solvent, a 2:1 chloroform:methanol solution was used,
which contained heneicosanol as internal fatty alcohol standard. The extracted
fraction was dried by rotary evaporation and dissolved in ethyl acetate10.
Quantiﬁcation of fatty alcohols was performed on the same gas chromatography–
mass spectrometry (GC–MS) system as used for FAME analysis or a GC–FID
system (Thermo Fisher Scientiﬁc). The GC programme for fatty alcohol
quantiﬁcation was as follows: initial temperature of 45 C hold for 2.5min; then
ramp to 220 C at a rate of 20 Cmin 1 and hold for 2min; ramp to 300 C at a
rate of 20 Cmin 1 and hold for 5min. Especially for docosanol analysis, the
following GC programme was used: initial temperature of 50 C, hold for 5min;
then ramp to 140 C at a rate of 10 Cmin 1 and hold for 10min; ramp to 310 C
at a rate of 15 Cmin 1 and hold for 7min.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁle or
available from the corresponding author upon reasonable request.
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